Clinical Trial: Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title:

Brief Summary: The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.

Detailed Summary:
Sponsor: Tel-Aviv Sourasky Medical Center

Current Primary Outcome: Number of participants with syncope and/or documented ventricular arrhythmia [ Time Frame: 5 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Change in corrected QT interval [ Time Frame: within 30 days of initiation of Ranolazine treatment ]

Original Secondary Outcome: Same as current

Information By: Tel-Aviv Sourasky Medical Center

Dates:
Date Received: November 12, 2012
Date Started: October 2012
Date Completion: November 2017
Last Updated: March 25, 2015
Last Verified: March 2015